Header

Cutaneous Skin Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 8 trials

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating pati...

Diagnosis: Melanoma, Cutaneous Skin Cancer

Phase: 2 / 3

Protocol Number: 15-724

A Study of DCC-2701 in Participants With Advanced Solid Tumors

The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to ...

Diagnosis: Cutaneous Skin Cancer

Phase: 1

Protocol Number: 14-031

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will ...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 15-217

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes...

Diagnosis: Cutaneous Skin Cancer, Other Trials

Phase:

Protocol Number: 16-388

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part will...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-529

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

This phase II trial studies how well talimogene laherparepvec works and nivolumab in treating patients with lymphomas that do not responded to treatment or non-melanoma skin cancers that have sprea...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-753

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with REGN28...

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-314

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

To assess the efficacy, safety and pharmacokinetics in subjects treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).

Diagnosis: Cutaneous Skin Cancer

Phase:

Protocol Number: 17-649

'